Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France
Fig 4
Probabilistic sensitivity analysis: Cost-Utility plan, for the base case analysis.